Flipping in the pore: Discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant s31n mutant of the influenza a virus m2 proton channel

Yibing Wu, Belgin Canturk, Hyunil Jo, Chunlong Ma, Eleonora Gianti, Michael L. Klein, Lawrence H. Pinto, Robert A. Lamb, Giacomo Fiorin, Jun Wang, William F. Degrado

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Influenza virus infections lead to numerous deaths and millions of hospitalizations each year. One challenge facing anti-influenza drug development is the heterogeneity of the circulating influenza viruses, which comprise several strains with variable susceptibility to antiviral drugs. For example, the wild-type (WT) influenza A viruses, such as the seasonal H1N1, tend to be sensitive to antiviral drugs, amantadine and rimantadine, while the S31N mutant viruses, such as the pandemic 2009 H1N1 (H1N1pdm09) and seasonal H3N2, are resistant to this class of drugs. Thus, drugs targeting both WT and the S31N mutant are highly desired. We report our design of a novel class of dual inhibitors along with their ion channel blockage and antiviral activities. The potency of the most active compound 11 in inhibiting WT and the S31N mutant influenza viruses is comparable with that of amantadine in inhibiting WT influenza virus. Solution NMR studies and molecular dynamics (MD) simulations of drug-M2 interactions supported our design hypothesis: namely, the dual inhibitor binds in the WT M2 channel with an aromatic group facing down toward the C-terminus, while the same drug binds in the S31N M2 channel with its aromatic group facing up toward the N-terminus. The flip-flop mode of drug binding correlates with the structure-activity relationship (SAR) and has paved the way for the next round of rational design of broad-spectrum antiviral drugs.

Original languageEnglish (US)
Pages (from-to)17987-17995
Number of pages9
JournalJournal of the American Chemical Society
Volume136
Issue number52
DOIs
StatePublished - Dec 31 2014

Fingerprint

Amantadine
Orthomyxoviridae
Viruses
Antiviral Agents
Protons
Pharmaceutical Preparations
Rimantadine
Influenza A virus
Pandemics
Virus Diseases
Molecular Dynamics Simulation
Drug Delivery Systems
Structure-Activity Relationship
Drug Interactions
Ion Channels
Drug interactions
Human Influenza
Hospitalization
Flip flop circuits
Molecular dynamics

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)
  • Biochemistry
  • Colloid and Surface Chemistry

Cite this

Flipping in the pore : Discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant s31n mutant of the influenza a virus m2 proton channel. / Wu, Yibing; Canturk, Belgin; Jo, Hyunil; Ma, Chunlong; Gianti, Eleonora; Klein, Michael L.; Pinto, Lawrence H.; Lamb, Robert A.; Fiorin, Giacomo; Wang, Jun; Degrado, William F.

In: Journal of the American Chemical Society, Vol. 136, No. 52, 31.12.2014, p. 17987-17995.

Research output: Contribution to journalArticle

Wu, Yibing ; Canturk, Belgin ; Jo, Hyunil ; Ma, Chunlong ; Gianti, Eleonora ; Klein, Michael L. ; Pinto, Lawrence H. ; Lamb, Robert A. ; Fiorin, Giacomo ; Wang, Jun ; Degrado, William F. / Flipping in the pore : Discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant s31n mutant of the influenza a virus m2 proton channel. In: Journal of the American Chemical Society. 2014 ; Vol. 136, No. 52. pp. 17987-17995.
@article{1302a3e47428402fa7dae86110a78090,
title = "Flipping in the pore: Discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant s31n mutant of the influenza a virus m2 proton channel",
abstract = "Influenza virus infections lead to numerous deaths and millions of hospitalizations each year. One challenge facing anti-influenza drug development is the heterogeneity of the circulating influenza viruses, which comprise several strains with variable susceptibility to antiviral drugs. For example, the wild-type (WT) influenza A viruses, such as the seasonal H1N1, tend to be sensitive to antiviral drugs, amantadine and rimantadine, while the S31N mutant viruses, such as the pandemic 2009 H1N1 (H1N1pdm09) and seasonal H3N2, are resistant to this class of drugs. Thus, drugs targeting both WT and the S31N mutant are highly desired. We report our design of a novel class of dual inhibitors along with their ion channel blockage and antiviral activities. The potency of the most active compound 11 in inhibiting WT and the S31N mutant influenza viruses is comparable with that of amantadine in inhibiting WT influenza virus. Solution NMR studies and molecular dynamics (MD) simulations of drug-M2 interactions supported our design hypothesis: namely, the dual inhibitor binds in the WT M2 channel with an aromatic group facing down toward the C-terminus, while the same drug binds in the S31N M2 channel with its aromatic group facing up toward the N-terminus. The flip-flop mode of drug binding correlates with the structure-activity relationship (SAR) and has paved the way for the next round of rational design of broad-spectrum antiviral drugs.",
author = "Yibing Wu and Belgin Canturk and Hyunil Jo and Chunlong Ma and Eleonora Gianti and Klein, {Michael L.} and Pinto, {Lawrence H.} and Lamb, {Robert A.} and Giacomo Fiorin and Jun Wang and Degrado, {William F.}",
year = "2014",
month = "12",
day = "31",
doi = "10.1021/ja508461m",
language = "English (US)",
volume = "136",
pages = "17987--17995",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "52",

}

TY - JOUR

T1 - Flipping in the pore

T2 - Discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant s31n mutant of the influenza a virus m2 proton channel

AU - Wu, Yibing

AU - Canturk, Belgin

AU - Jo, Hyunil

AU - Ma, Chunlong

AU - Gianti, Eleonora

AU - Klein, Michael L.

AU - Pinto, Lawrence H.

AU - Lamb, Robert A.

AU - Fiorin, Giacomo

AU - Wang, Jun

AU - Degrado, William F.

PY - 2014/12/31

Y1 - 2014/12/31

N2 - Influenza virus infections lead to numerous deaths and millions of hospitalizations each year. One challenge facing anti-influenza drug development is the heterogeneity of the circulating influenza viruses, which comprise several strains with variable susceptibility to antiviral drugs. For example, the wild-type (WT) influenza A viruses, such as the seasonal H1N1, tend to be sensitive to antiviral drugs, amantadine and rimantadine, while the S31N mutant viruses, such as the pandemic 2009 H1N1 (H1N1pdm09) and seasonal H3N2, are resistant to this class of drugs. Thus, drugs targeting both WT and the S31N mutant are highly desired. We report our design of a novel class of dual inhibitors along with their ion channel blockage and antiviral activities. The potency of the most active compound 11 in inhibiting WT and the S31N mutant influenza viruses is comparable with that of amantadine in inhibiting WT influenza virus. Solution NMR studies and molecular dynamics (MD) simulations of drug-M2 interactions supported our design hypothesis: namely, the dual inhibitor binds in the WT M2 channel with an aromatic group facing down toward the C-terminus, while the same drug binds in the S31N M2 channel with its aromatic group facing up toward the N-terminus. The flip-flop mode of drug binding correlates with the structure-activity relationship (SAR) and has paved the way for the next round of rational design of broad-spectrum antiviral drugs.

AB - Influenza virus infections lead to numerous deaths and millions of hospitalizations each year. One challenge facing anti-influenza drug development is the heterogeneity of the circulating influenza viruses, which comprise several strains with variable susceptibility to antiviral drugs. For example, the wild-type (WT) influenza A viruses, such as the seasonal H1N1, tend to be sensitive to antiviral drugs, amantadine and rimantadine, while the S31N mutant viruses, such as the pandemic 2009 H1N1 (H1N1pdm09) and seasonal H3N2, are resistant to this class of drugs. Thus, drugs targeting both WT and the S31N mutant are highly desired. We report our design of a novel class of dual inhibitors along with their ion channel blockage and antiviral activities. The potency of the most active compound 11 in inhibiting WT and the S31N mutant influenza viruses is comparable with that of amantadine in inhibiting WT influenza virus. Solution NMR studies and molecular dynamics (MD) simulations of drug-M2 interactions supported our design hypothesis: namely, the dual inhibitor binds in the WT M2 channel with an aromatic group facing down toward the C-terminus, while the same drug binds in the S31N M2 channel with its aromatic group facing up toward the N-terminus. The flip-flop mode of drug binding correlates with the structure-activity relationship (SAR) and has paved the way for the next round of rational design of broad-spectrum antiviral drugs.

UR - http://www.scopus.com/inward/record.url?scp=84920163405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920163405&partnerID=8YFLogxK

U2 - 10.1021/ja508461m

DO - 10.1021/ja508461m

M3 - Article

C2 - 25470189

AN - SCOPUS:84920163405

VL - 136

SP - 17987

EP - 17995

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 52

ER -